<DOC>
	<DOCNO>NCT02245945</DOCNO>
	<brief_summary>The purpose trial ass safety acceptability Tenofovir ( TFV ) 1 % gel adolescent female 12 week minimum twice weekly dose follow BAT24 regimen .</brief_summary>
	<brief_title>Safety Acceptability Tenofovir 1 % Gel Adolescent Females</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age 15 17 year , inclusive , per site policy General good health ( volunteer history per investigator discretion ) without clinically significant systemic disease ( include , limited significant liver disease/hepatitis , gastrointestinal disease , kidney disease , thyroid disease , osteoporosis bone disease , diabetes ) Able communicate speak write English Willing follow instruction regard vaginal activity vaginal product follow : 1 . Willing abstain vaginal activity , include intercourse , 48 hour prior Visit 2 48 hour prior Visit 7 2 . Willing abstain use vaginal product study product include spermicide , lubricant , douche duration study participation . Note : Tampons may use menses , pad use intermenstrual spotting bleeding . Assessment onset progression puberty measure Tanner Stage 4 5 History consensual penilevaginal intercourse ( least one episode participant 's lifetime ) Negative urine pregnancy test Use effective method contraception least past 30 day ( per participant report ) intend use duration study participation . Effective method include : 1 . Hormonal method ( exclude contraceptive ring ) 2 . Intrauterine contraception ( IUC ) Note : An IUC must place least 15 day prior enrollment Willing give voluntary assent , comply study procedure require protocol assent willing parent/guardian provide write informed consent participation per Institutional Review Board ( IRB ) requirement . Emancipated minor may give informed consent . Known adverse reaction study product ( ever ) latex , per participant report Nontherapeutic injection drug use last 12 calendar month Postexposure prophylaxis ( PEP ) HIV1 exposure within last 6 calendar month Currently pregnant within 30 day last pregnancy outcome . Note : If recently pregnant must least two spontaneous menses since pregnancy outcome . History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix within last 14 day Intention become pregnant next 6 month Currently breastfeed breastfed infant last two month , plan breastfeed course study Positive HIV Grade 2 high per Division AIDS ( DAIDS ) Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) follow : 1 . Alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) 2 . Creatinine 3 . Hemoglobin 4 . Platelet count 5 . Hepatitis B surface antigen ( HBsAg ) Note : Otherwise eligible participant exclusionary test result ( ) list may retested maximum one time nonexclusionary result document within 30 day provide informed consent , may enrol . Clinically apparent Grade 2 high pelvic examination finding ( observe study staff ) per Female Genital Grading Table Use Microbicide Studies ( Addendum 1 DAIDS Table Grading Adult Pediatric Adverse Events , Version 1.0 , December 2004 ( Clarification date August 2009 ) Note : 1 ) Cervical bleeding associate speculum insertion and/or specimen collection judge within range normal accord clinical judgment Principal Investigator/designee consider expect nonmenstrual bleeding exclusionary . 2 ) Otherwise eligible participant exclusionary pelvic examination finding may enrol /randomized improvement finding nonexclusionary grade resolution document within 30 day provide informed consent Screening . Current pelvic inflammatory disease ( PID ) sexually transmit infection require treatment per current Centers Disease Control Prevention ( CDC ) guideline ( e.g. , Trichomonas vaginalis , Neisseria gonorrhea ( GC ) , Chlamydia trachomatis ( CT ) , active herpes outbreak ) Symptomatic vulvovaginal candidiasis , symptomatic bacterial vaginosis ( BV ) urinary tract infection ( UTI ) Note : Otherwise eligible participant symptomatic vulvovaginal candidiasis , BV UTI prior genital sample Visit 2 offer treatment may continue study complete treatment symptom finding resolve . Systemic use last two week anticipate use study follow : corticosteroid , antibiotic , antifungal , antiviral ( e.g. , acyclovir valacyclovir ) antiretrovirals ( e.g. , Viread® , Atripla® , Emtriva® , Complera® , Stribild® ) . Note : Participants avoid nonsteroidal antiinflammatory drug ( NSAIDs ) except treatment dysmenorrhea menses . Participants may use Tylenol® asneeded daily basis study . Participation investigational trial ( device , drug , vaginal trial ) within last 30 day plan participation investigational trial study Any condition , opinion Principal Investigator ( PI ) designee , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>prevention</keyword>
</DOC>